Columbus Brown, MD
Rheumatology · Little Rock, ARNPI 1558321612
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 993 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 37 manufacturers reported payments, led by Amgen at 24.5% of the total. Reporting peaked in 2020 at $3,591 and has fallen 51.7% since, to $1,736 in 2025.
Across 993 payments — averaging $18.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$4K
- AbbVie$4K
- GSK$2K
- Pfizer$1K
- Mallinckrodt Hospital Products Inc.$1K
- Johnson & Johnson$940
- plus $5K from 31 others
What the payments were for
- Consulting fees$1801%
- Food & beverage$17,68398%
- Education$1721%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 233 | $4,419 |
| AbbVie | 208 | $3,557 |
| GSK | 91 | $1,669 |
| Pfizer | 75 | $1,324 |
| Mallinckrodt Hospital Products Inc. | 62 | $1,186 |
| Johnson & Johnson | 52 | $940 |
| AstraZeneca(2 entities) | 34 | $658 |
| UCB, Inc. | 37 | $631 |
| Novartis | 33 | $612 |
| Lilly USA, LLC | 32 | $525 |
| E.r. Squibb & Sons, L.L.C. | 26 | $431 |
| Mallinckrodt Enterprises LLC | 14 | $272 |
| Aurinia Pharma U.S., Inc. | 11 | $256 |
| Genentech USA, Inc. | 9 | $175 |
| Organon | 10 | $170 |
| Boehringer Ingelheim | 8 | $165 |
| Bristol Myers Squibb | 12 | $162 |
| ANI Pharmaceuticals, Inc. | 6 | $142 |
| Fresenius Kabi USA, LLC | 7 | $128 |
| Regeneron Healthcare Solutions, Inc. | 7 | $124 |
| Sanofi | 4 | $82 |
| Invivyd Inc | 3 | $66 |
| Eisai Inc. | 4 | $63 |
| Merck | 2 | $30 |
| Sandoz | 1 | $28 |
| CSL Behring | 1 | $27 |
| MDD US Operations, LLC | 1 | $22 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Forte Bio-pharma LLC | 1 | $20 |
| Pacira Therapeutics, Inc. | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Scilex Pharmaceuticals Inc. | 1 | $17 |
| Biodelivery Sciences International, Inc. | 1 | $16 |
| Tonix Medicines, Inc. | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $13 |
| Boston Scientific | 1 | $12 |
How this compares
$18,035 in reported general payments places this provider in the 85th percentile of 48 rheumatology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 49 | $359,287 |
| BenlystaBelimumab | 53 | $284,541 |
| Skyrizi PenRisankizumab-Rzaa | 11 | $222,809 |
| EnbrelEtanercept | 23 | $169,997 |
| Humira PenAdalimumab | 23 | $168,902 |
| Humira(Cf) PenAdalimumab | 19 | $138,496 |
| Actemra ActpenTocilizumab | 21 | $111,644 |
| Cimzia (2 Pack)Certolizumab Pegol | 16 | $93,127 |
| OrenciaAbatacept | 14 | $82,575 |
| Taltz AutoinjectorIxekizumab | 11 | $72,700 |
| ForteoTeriparatide | 12 | $49,763 |
| Hydroxychloroquine Sulfate | 669 | $21,580 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 676 | $13,680 |
| Pregabalin | 265 | $8,361 |
| BelsomraSuvorexant | 19 | $7,900 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBenlysta | $1,669 | $284,54153 claims |
| AmgenEnbrel | $4,419 | $169,99723 claims |
| UCB, Inc.Cimzia (2 Pack) | $631 | $93,12716 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $431 | $82,57514 claims |
| Lilly USA, LLCForteo | $525 | $49,76312 claims |
| MerckBelsomra | $30 | $7,90019 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $20 | $5,52411 claims |
| AbbVieSavella | $3,557 | $2,98213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 48 rheumatology providers in Arkansas.
Other rheumatology in Little Rock
- Cummins LueLittle Rock$76K
- Jasen ChiLittle Rock$30K
- Richard HoukLittle Rock$25K
- Renee Peterkin-MccalmanLittle Rock$16K
- Daniel GonzalezLittle Rock$12K
- Safwan SakrLittle Rock$11K
- Alina VoineaLittle Rock$8K
- Tamer AlsebaiLittle Rock$6K
- Mavi Rivera PavonLittle Rock$5K
- Rina GuptaLittle Rock$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.